Cyclophosphamide for interstitial lung disease-associated acute respiratory failure: mortality, clinical response and radiological characteristics

BACKGROUND: Treatment for interstitial lung disease (ILD) patients with acute respiratory failure (ARF) is challenging, and literature to guide such treatment is scarce. The reported in-hospital mortality rates of ILD patients with ARF are high (62–66%). Cyclophosphamide is considered a second-line...

Descripción completa

Detalles Bibliográficos
Autores principales: van Gemert, Johanna P., van den Berk, Inge A. H., Nossent, Esther J., Heunks, Leo M. A., Jonkers, Rene E., Vlaar, Alexander P., Bonta, Peter I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8316896/
https://www.ncbi.nlm.nih.gov/pubmed/34320981
http://dx.doi.org/10.1186/s12890-021-01615-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8316896/
https://www.ncbi.nlm.nih.gov/pubmed/34320981
http://dx.doi.org/10.1186/s12890-021-01615-2

Ejemplares similares